Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
Saved in:
| Title: | Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET. |
|---|---|
| Authors: | Gennari A; Department of Translational Medicine, University of Piemonte Orientale, Novara; Division of Medical Oncology, Maggiore University Hospital, Novara, Italy. Electronic address: alessandra.gennari@uniupo.it., Brain E; Department of Medical Oncology, Institut Curie-Hôpital René Huguenin, Saint-Cloud, France., De Censi A; Medical Oncology, E.O. Ospedali Galliera, Genova., Nanni O; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Wuerstlein R; Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany., Frassoldati A; Clinical Oncology, S. Anna University Hospital, Ferrara, Italy., Cortes J; International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain., Rossi V; Division of Medical Oncology, Maggiore University Hospital, Novara, Italy., Palleschi M; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Alberini JL; Nuclear Medicine Department Centre Georges-Francois Leclerc, Dijon Cedex, France., Matteucci F; Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo studio dei tumori (IRST) -'Dino Amadori', Meldola., Piccardo A; Department of Nuclear Medicine, E.O. Ospedali Galliera, Genoa., Sacchetti G; Division of Nuclear Medicine Unit, Maggiore University Hospital, Novara, Italy., Ilhan H; Department of Nuclear Medicine, LMU University Hospital, Munich, Germany., D'Avanzo F; Division of Medical Oncology, Maggiore University Hospital, Novara, Italy., Ruffilli B; Department of Translational Medicine, University of Piemonte Orientale, Novara., Nardin S; Medical Oncology Unit 1, IRCCS-Ospedale Policlinico San Martino, Genoa., Monti M; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Puntoni M; Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma., Fontana V; Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa, Italy., Boni L; Department of Clinical Epidemiology, IRCSS Ospedale Policlinico San Martino, Genoa, Italy., Harbeck N; Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany. |
| Corporate Authors: | ET-FES Collaborative Group |
| Source: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2024 Jun; Vol. 35 (6), pp. 549-558. Date of Electronic Publication: 2024 Feb 28. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
